Gestational diabetes & diabetes in pregnancy
A Systematic Review and Meta-Analysis Examining the Risk of Adverse Pregnancy and Neonatal Outcomes in Women with Isolated Hypothyroxinemia in Pregnancy
Authors' conclusion
There is evidence suggesting that IH in pregnancy may be associated with an increased risk of adverse pregnancy and neonatal outcomes. However, it is unclear whether LT4 may mitigate the risk of these adverse outcomes.
Study context
- Population
- Pregnant women with isolated hypothyroxinemia (IH); RCTs and cohort studies in PubMed, Embase, Web of Science and Cochrane CENTRAL from inception to December 202221 articles
- Comparison
- Isolated hypothyroxinemia vs euthyroid pregnancies; Levothyroxine (LT4) treatment status
- Outcome
- Adverse pregnancy and neonatal outcomes, IH vs euthyroid
Methodological detailsrandom-effects meta-analysis
- Random-effects meta-analysis
Pooled result
As reported in the abstract
IH vs EuthyroidEstimate (CI)
I2 = 9%
RR, preterm birth 1.35(1.16–1.56)
I2 = 0%
RR, premature rupture of membranes 1.41(1.08–1.84)
I2 = 76%
RR, gestational diabetes 1.34(1.07–1.67)
I2 = 42%
RR, macrosomia 1.62(1.31–2.02)
I2 = 0%
RR, fetal distress 1.72(1.15–2.56)
Further pooled results
- No statistically significant differences in adverse outcomes according to LT4 treatment status (4 articles)
Original publication
A Systematic Review and Meta-Analysis Examining the Risk of Adverse Pregnancy and Neonatal Outcomes in Women with Isolated Hypothyroxinemia in Pregnancy. Thyroid. Published 26 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →